The Complete Guide to Direct to Patient (DTP) Drug Programs: Strategy, Economics, and Affordability Integration

Direct to Patient (DTP) programs are transforming how drug manufacturers reach patients outside traditional insurance, with BMS, Novartis, Amgen, and Eli Lilly launching programs at 40–80% off list price. But is DTP right for your brand, and does it actually lower patient costs? This three-part series covers DTP fundamentals and vendor models (Part 1), script-level economics and payer rebate risks (Part 2), and how to integrate DTP into an Affordability Center of Excellence alongside other patient support levers (Part 3).